Zaleplon controlled release - SkyePharma/Somnus

Drug Profile

Zaleplon controlled release - SkyePharma/Somnus

Alternative Names: SKP-1041

Latest Information Update: 09 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SkyePharma AG
  • Developer Somnus Therapeutics
  • Class Acetamides; Hypnosedatives; Pyrimidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Sleep maintenance insomnia

Most Recent Events

  • 23 Apr 2012 Zaleplon controlled release - SkyePharma/Somnus is available for licensing as of 23 Apr 2012. www.somnusthera.com
  • 16 Jun 2011 Final efficacy data from a phase II trial in Sleep maintenance insomnia released by Somnus Therapeutics
  • 28 Feb 2011 Somnus Therapeutics completes a phase II trial in Sleep maintenance insomnia in USA (NCT00878553)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top